In search of a small-molecule inhibitor for respiratory syncytial virus

Janet L. Douglas

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Respiratory syncytial virus has been an ongoing health problem for 50 years. Hospitalization rates due to virus-induced respiratory illness continue to be substantial for infants, small children, the elderly and the immunocompromised. The only currently available treatments are a broad-spectrum antiviral and two immunoprophylactic antibodies, all of which are reserved for high-risk patients. The combination of this limited therapeutic repertoire and the lack of a vaccine clearly demonstrates the need to continue the search for more efficacious and safe agents against respiratory syncytial virus. The following is a review on the current progress of that search.

Original languageEnglish (US)
Pages (from-to)625-639
Number of pages15
JournalExpert Review of Anti-Infective Therapy
Issue number4
StatePublished - Aug 2004
Externally publishedYes


  • Antivirals
  • Entry/fusion
  • Inhibitor
  • RSV
  • Respiratory syncytial virus
  • Ribavirin
  • Small molecule

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases


Dive into the research topics of 'In search of a small-molecule inhibitor for respiratory syncytial virus'. Together they form a unique fingerprint.

Cite this